-
1 Comment
bioMérieux S.A is currently in a long term downtrend where the price is trading 16.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.2.
Finally, its free cash flow fell by 26.1% to $86M since the same quarter in the previous year.
Based on the above factors, bioMérieux S.A gets an overall score of 1/5.
| Sector | Healthcare |
|---|---|
| Industry | Diagnostics & Research |
| Exchange | F |
| CurrencyCode | EUR |
| ISIN | FR0013280286 |
| Beta | 0.48 |
|---|---|
| Market Cap | 14B |
| PE Ratio | 32.86 |
| Target Price | None |
| Dividend Yield | 0.7% |
bioMérieux S.A. develops and markets in vitro diagnostic solutions for infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemase producing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO or 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDAS, a specific marker of severe bacterial infections/sepsis. It also develops Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. It has partnership with Boehringer Ingelheim and Evotec. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for EYWN.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
